SNYNF (Sanofi) YoY EBITDA Growth : 24.16% (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Sanofi YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Sanofi's YoY EBITDA Growth for the quarter that ended in Dec. 2024 was 24.16%.

Sanofi's EBITDA per Share for the six months ended in Dec. 2024 was $5.39.

Sanofi YoY EBITDA Growth Historical Data

The historical data trend for Sanofi's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi YoY EBITDA Growth Chart

Sanofi Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

YoY EBITDA Growth

Get a 7-Day Free Trial

83.20

-39.97

9.86

-13.17

-6.97

Sanofi Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
YoY EBITDA Growth	Get a 7-Day Free Trial															18.48	14.86	-34.24	-28.89	24.16

Sanofi YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Sanofi's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (A: Dec. 2024 )
=	(EBITDA per Share (A: Dec. 2024 )	-	EBITDA per Share (A: Dec. 2023 ))	/	\| EBITDA per Share (A: Dec. 2023 ) \|
=	(9.197	-	9.886)	/	\| 9.886 \|
=	-6.97 %

Sanofi's YoY EBITDA Growth for the quarter that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2024 )
=	(EBITDA per Share (Q: Dec. 2024 )	-	EBITDA per Share (Q: Dec. 2023 ))	/	\| EBITDA per Share (Q: Dec. 2023 )) \|
=	(5.386	-	4.338)	/	\| 4.338 \|
=	24.16 %

Sanofi YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Sanofi's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (OTCPK:SNYNF) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

SNY:USA SAN1:Mexico SNY N:Mexico 1SAN:Italy 0A2V:UK SANp:UK 0O59:UK SAN:France SNW:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SNW:Bulgaria SANO:Austria

Address

46, Avenue de la Great Army, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.